BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $114
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains a Market Perform rating on Neurocrine Biosciences (NASDAQ:NBIX) but lowers the price target from $128 to $114.
October 17, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BMO Capital has maintained its Market Perform rating on Neurocrine Biosciences but has lowered the price target from $128 to $114, indicating a less optimistic outlook.
The lowering of the price target from $128 to $114 by BMO Capital suggests a less optimistic view on the stock's potential, which could lead to a negative short-term impact on NBIX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100